O30: REKLAIM: A first in human phase Ib clinical trial of FBX-101 (AAVrh10.GALC) intravenously administered after UCBT for infantile Krabbe disease

• Maria Escolar,
• Mark Vander Lugt,
• Raymond Wang,
• Juan Ruiz,
• Michele Poe,
• Paul Szabolcs

Affiliations

Maria Escolar

Forge Biologics/University of Pittsburgh

Mark Vander Lugt

University of Michigan

Raymond Wang

Children's Hospital of Orange County

Juan Ruiz

Forge Biologics

Michele Poe

Forge Biologics

Paul Szabolcs

University of Pittsburgh